Posaconazole: A broad-spectrum triazole antifungal

Lancet Infectious Diseases

Volumn 5, Issue 12, 2005, Pages 775-785

  Torres, Harrys A ^a   Hachem, Ray Y ^a   Chemaly, Roy F ^a   Kontoyiannis, Dimitrios P ^a   Raad, Issam I ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ASTEMIZOLE; CASPOFUNGIN; CIMETIDINE; CISAPRIDE; CYCLOSPORIN A; ENZYME INHIBITOR; FLUCONAZOLE; FLUCYTOSINE; GLIPIZIDE; INDINAVIR; ITRACONAZOLE; LAMIVUDINE; PHENYTOIN; POSACONAZOLE; PYRROLE DERIVATIVE; QUINIDINE; RAPAMYCIN; RAVUCONAZOLE; RIFABUTIN; RITONAVIR; TACROLIMUS; TERBINAFINE; TERFENADINE; TRIAZOLE DERIVATIVE; UNINDEXED DRUG; VORICONAZOLE; ZIDOVUDINE;

ABDOMINAL PAIN; ANOREXIA; ASPERGILLOSIS; ASPERGILLUS; ASTHENIA; CANDIDA; CLINICAL TRIAL; COLOR VISION; CONFUSION; CONSTIPATION; CRYPTOCOCCUS NEOFORMANS; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG METABOLISM; EYE PAIN; FATIGUE; FEVER; FLATULENCE; FUNGUS; FUSARIOSIS; FUSARIUM; GASTROINTESTINAL DISEASE; HALLUCINATION; HEADACHE; HUMAN; HYPOTENSION; LIVER; LIVER DYSFUNCTION; MENINGITIS; MENSTRUATION DISORDER; MOULD; MUCORMYCOSIS; MUSCULOSKELETAL DISEASE; MYCOSIS; NAUSEA; NEUTROPENIA; NONHUMAN; PAIN; PERIPHERAL NEUROPATHY; PHOTOPHOBIA; PHOTOPSIA; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SOMNOLENCE; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; YEAST; ZYGOMYCETES;

ANTIBIOTICS, ANTIFUNGAL; DRUG RESISTANCE, FUNGAL; FUNGI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOSES; TREATMENT OUTCOME; TRIAZOLES;

EID: 28044445699     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(05)70297-8     Document Type: Review

References (139)

1. KA Marr, T Patterson, D Denning Aspergillosis. Pathogenesis, clinical manifestations, and therapy Infect Dis Clin North Am 16 2002 875 894
2. TF Patterson, WR Kirkpatrick, M White Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes Medicine (Baltimore) 79 2000 250 260
3. A Antoniadou, HA Torres, RE Lewis Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy Medicine (Baltimore) 82 2003 309 321
4. HA Torres, GA Rivero, RE Lewis, R Hachem, II Raad, DP Kontoyiannis Aspergillosis caused by non-fumigatus Aspergillus species: risk factors and in vitro susceptibility compared with Aspergillus fumigatus Diagn Microbiol Infect Dis 46 2003 25 28
5. H Torres, D Kontoyiannis Hyalohyphomycosis (other than aspergillosis and penicilliosis) WE Dismukes PG Pappas JD Sobel Oxford textbook of clinical mycology 1st edn. 2003 Oxford University Press New York, NY 252 270
6. DP Kontoyiannis, GP Bodey Invasive aspergillosis in 2002: an update Eur J Clin Microbiol Infect Dis 21 2002 161 172
7. M Nucci, KA Marr, F Queiroz-Telles Fusarium infection in hematopoietic stem cell transplant recipients Clin Infect Dis 38 2004 1237 1242
8. D Abi-Said, E Anaissie, O Uzun, I Raad, H Pinzcowski, S Vartivarian The epidemiology of hematogenous candidiasis caused by different Candida species Clin Infect Dis 24 1997 1122 1128
9. DW Denning Echinocandin antifungal drugs Lancet 362 2003 1142 1151
10. HW Boucher, AH Groll, CC Chiou, TJ Walsh Newer systemic antifungal agents: pharmacokinetics, safety and efficacy Drugs 64 2004 1997 2020
11. LB Johnson, CA Kauffman Voriconazole: a new triazole antifungal agent Clin Infect Dis 36 2003 630 637
12. DP Kontoyiannis, R Hachem, RE Lewis Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies Cancer 98 2003 292 299
13. DP Kontoyiannis, RE Lewis Antifungal drug resistance of pathogenic fungi Lancet 359 2002 1135 1144
14. R Courtney, E Radwanski, J Lim, M Laughlin Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men Antimicrob Agents Chemother 48 2004 804 808
15. R Petraitiene, V Petraitis, AH Groll Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia Antimicrob Agents Chemother 45 2001 857 869
16. A Chen, JD Sobel Emerging azole antifungals Expert Opin Emerg Drugs 10 2005 21 33
17. AJ Ullmann, JH Lipton, DH Vesole A multicenter trial of oral posaconazole vs. fluconazole for the prophylaxis of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation with graft-vs.-host disease Mycoses 48 suppl 2 2005 26a 27a
18. TJ Walsh, MA Viviani, E Arathoon New targets and delivery systems for antifungal therapy Med Mycol 38 suppl 1 2000 335 347
19. E Dannaoui, J Meletiadis, JW Mouton, JF Meis, PE Verweij In vitro susceptibilities of zygomycetes to conventional and new antifungals J Antimicrob Chemother 51 2003 45 52
20. F Barchiesi, D Arzeni, AW Fothergill In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens Antimicrob Agents Chemother 44 2000 226 229
21. MA Pfaller, SA Messer, RJ Hollis, RN Jones In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans Antimicrob Agents Chemother 45 2001 2862 2864
22. MA Pfaller, SA Messer, L Boyken In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program Diagn Microbiol Infect Dis 48 2004 201 205
23. Sabatelli FJ, Leobenberg D, Mendrick A, Patel R, Norris C, McNicholas PM. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against approximately 18,000 strains of clinically significant yeasts and moulds. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; Oct 30-Nov 2, 2004.
24. A Espinel-Ingroff Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts J Clin Microbiol 36 1998 2950 2956
25. MA Pfaller, SA Messer, L Boyken, S Tendolkar, RJ Hollis, DJ Diekema Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 and 2002 J Clin Microbiol 42 2004 3142 3146
26. J Mosquera, DW Denning Azole cross-resistance in Aspergillus fumigatus Antimicrob Agents Chemother 46 2002 556 557
27. D Law, CB Moore, DW Denning Activity of SCH 56592 compared with those of fluconazole and itraconazole against Candida spp Antimicrob Agents Chemother 41 1997 2310 2311
28. A Espinel-Ingroff In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature Rev Iberoam Micol 20 2003 121 136
29. AJ Carrillo-Munoz, G Quindos, M Ruesga Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections J Antimicrob Chemother 55 2005 317 319
30. L Ostrosky-Zeichner, JH Rex, PG Pappas Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States Antimicrob Agents Chemother 47 2003 3149 3154
31. X Li, N Brown, AS Chau Changes in susceptibility to posaconazole in clinical isolates of Candida albicans J Antimicrob Chemother 53 2004 74 80
32. HK Munayyer, PA Mann, AS Chau Posaconazole is a potent inhibitor of sterol 14alpha-demethylation in yeasts and molds Antimicrob Agents Chemother 48 2004 3690 3696
33. AH Groll, TJ Walsh Posaconazole: clinical pharmacology and potential for management of fungal infections Expert Rev Anti Infect Ther 3 2005 467 487
34. MA Pfaller, SA Messer, L Boyken Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004) J Clin Microbiol 43 2005 2163 2167
35. JR Perfect, GM Cox, RK Dodge, WA Schell In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans Antimicrob Agents Chemother 40 1996 1910 1913
36. AK Zaas, M Boyce, W Schell, BA Lodge, JL Miller, JR Perfect Risk of fungemia due to Rhodotorula and antifungal susceptibility testing of Rhodotorula isolates J Clin Microbiol 41 2003 5233 5235
37. NI Paphitou, L Ostrosky-Zeichner, VL Paetznick, JR Rodriguez, E Chen, JH Rex In vitro antifungal susceptibilities of Trichosporon species Antimicrob Agents Chemother 46 2002 1144 1146
38. DJ Diekema, SA Messer, RJ Hollis, RN Jones, MA Pfaller Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi J Clin Microbiol 41 2003 3623 3626
39. F Marco, MA Pfaller, SA Messer, RN Jones In vitro activity of a new triazole antifungal agent, SCH 56592, against clinical isolates of filamentous fungi Mycopathologia 141 1998 73 77
40. Hayette MP, Amadore A, Seidel L, et al. Comparative in vitro activity of amphotericine B, itraconazole, voriconazole and posaconazole against Aspergillus fumigatus. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; Dec 6-9, 2001.
41. EK Manavathu, JL Cutright, D Loebenberg, PH Chandrasekar A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592) J Antimicrob Chemother 46 2000 229 234
42. PA Mann, RM Parmegiani, SQ Wei Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14 alpha-demethylase Antimicrob Agents Chemother 47 2003 577 581
43. RY Hachem, DP Kontoyiannis, MR Boktour Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies Cancer 101 2004 1594 1600
44. JR Graybill, S Hernandez, R Bocanegra, LK Najvar Antifungal therapy of murine Aspergillus terreus infection Antimicrob Agents Chemother 48 2004 3715 3719
45. WJ Steinbach, DK Benjamin Jr, DP Kontoyiannis Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases Clin Infect Dis 39 2004 192 198
46. TJ Walsh, V Petraitis, R Petraitiene Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B J Infect Dis 188 2003 305 319
47. NI Paphitou, L Ostrosky-Zeichner, VL Paetznick, JR Rodriguez, E Chen, JH Rex In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results Antimicrob Agents Chemother 46 2002 3298 3300
48. HA Torres, II Raad, DP Kontoyiannis Infections caused by Fusarium species J Chemother 15 suppl 2 2003 28 35
49. QN Sun, AW Fothergill, DI McCarthy, MG Rinaldi, JR Graybill In vitro activities of posaconazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes Antimicrob Agents Chemother 46 2002 1581 1582
50. Gonzalez G, Tijerina R, Najvar L, et al. Therapeutic efficacy of posaconazole in a murine Pseudallescheria boydii infection. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; Dec 6-9, 2001.
51. GM Gonzalez, R Tijerina, LK Najvar Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays Antimicrob Agents Chemother 47 2003 1436 1438
52. A Safdar Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole Clin Infect Dis 34 2002 1415 1417
53. MA Pfaller, SA Messer, RJ Hollis, RN Jones Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000 Antimicrob Agents Chemother 46 2002 1032 1037
54. GM Gonzalez, AW Fothergill, DA Sutton, MG Rinaldi, D Loebenberg In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi Med Mycol 43 2005 281 284
55. GM Gonzalez, R Tijerina, LK Najvar In vitro and in vivo activities of posaconazole against Coccidioides immitis Antimicrob Agents Chemother 46 2002 1352 1356
56. M Nucci, T Akiti, G Barreiros Nosocomial fungemia due to Exophiala jeanselmei var. jeanselmei and a Rhinocladiella species: newly described causes of bloodstream infection J Clin Microbiol 39 2001 514 518
57. A Cacciapuoti, M Gurnani, J Halpern, C Norris, R Patel, D Loebenberg Interaction between posaconazole and amphotericin B in concomitant treatment against Candida albicans in vivo Antimicrob Agents Chemother 49 2005 638 642
58. F Barchiesi, E Spreghini, AM Schimizzi Posaconazole and amphotericin B combination therapy against Cryptococcus neoformans infection Antimicrob Agents Chemother 48 2004 3312 3316
59. LK Najvar, A Cacciapuoti, S Hernandez Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories Antimicrob Agents Chemother 48 2004 758 764
60. Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetics and pharmacodynamics of posaconazole (SCH 56592) in a neutropenic animal model of invasive pulmonary aspergillosis. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Canada; Sept 7-12, 2000.
61. M Lozano-Chiu, S Arikan, VL Paetznick, EJ Anaissie, D Loebenberg, JH Rex Treatment of murine fusariosis with SCH 56592 Antimicrob Agents Chemother 43 1999 589 591
62. E Dannaoui, JF Meis, D Loebenberg, PE Verweij Activity of posaconazole in treatment of experimental disseminated zygomycosis Antimicrob Agents Chemother 47 2003 3647 3650
63. QN Sun, LK Najvar, R Bocanegra, D Loebenberg, JR Graybill In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model Antimicrob Agents Chemother 46 2002 2310 2312
64. M Simitsopoulou, C Gil-Lamaignere, N Avramidis Antifungal activities of posaconazole and granulocyte-macrophage colony-stimulating factor ex vivo and in mice with disseminated infection due to Scedosporium prolificans Antimicrob Agents Chemother 48 2004 3801 3805
65. P Connolly, LJ Wheat, C Schnizlein-Bick Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice Antimicrob Agents Chemother 44 2000 2604 2608
66. AM Sugar, XP Liu In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 40 1996 1314 1316
67. JR Graybill, LK Najvar, E Johnson, R Bocanegra, D Loebenberg Posaconazole therapy of disseminated phaeohyphomycosis in a murine model Antimicrob Agents Chemother 48 2004 2288 2291
68. HM Al-Abdely, L Najvar, R Bocanegra SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei") Antimicrob Agents Chemother 44 2000 1159 1162
69. HM Al-Abdely, LK Najvar, R Bocanegra, JR Graybill Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana Antimicrob Agents Chemother 49 2005 1701 1707
70. DP Kontoyiannis, RE Lewis Toward more effective antifungal therapy: the prospects of combination therapy Br J Haematol 126 2004 165 175
71. S Perea, G Gonzalez, AW Fothergill, DA Sutton, MG Rinaldi In vitro activities of terbinafine in combination with fluconazole, itraconazole, voriconazole, and posaconazole against clinical isolates of Candida glabrata with decreased susceptibility to azoles J Clin Microbiol 40 2002 1831 1833
72. ER Oliveira, AW Fothergill, WR Kirkpatrick, BJ Coco, TF Patterson, SW Redding In vitro interaction of posaconazole and caspofungin against clinical isolates of Candida glabrata Antimicrob Agents Chemother 49 2005 3544 3545
73. F Barchiesi, AM Schimizzi, LK Najvar Interactions of posaconazole and flucytosine against Cryptococcus neoformans Antimicrob Agents Chemother 45 2001 1355 1359
74. DP Kontoyiannis, RE Lewis, N Sagar, G May, RA Prince, KV Rolston Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy Antimicrob Agents Chemother 44 2000 2915 2918
75. RE Lewis, RA Prince, J Chi, DP Kontoyiannis Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis Antimicrob Agents Chemother 46 2002 3208 3214
76. EK Manavathu, GJ Alangaden, PH Chandrasekar Differential activity of triazoles in two-drug combinations with the echinocandin caspofungin against Aspergillus fumigatus J Antimicrob Chemother 51 2003 1423 1425
77. AC Patera, F Menzel, C Jackson Effect of granulocyte colony-stimulating factor combination therapy on efficacy of posaconazole (SCH56592) in an inhalation model of murine pulmonary aspergillosis Antimicrob Agents Chemother 48 2004 3154 3158
78. JR Graybill, R Bocanegra, LK Najvar, D Loebenberg, MF Luther Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression Antimicrob Agents Chemother 42 1998 2467 2473
79. R Herbrecht Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections Int J Clin Pract 58 2004 612 624
80. R Courtney, D Wexler, E Radwanski, J Lim, M Laughlin Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults Br J Clin Pharmacol 57 2004 218 222
81. F Ezzet, D Wexler, R Courtney, G Krishna, J Lim, M Laughlin Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations Clin Pharmacokinet 44 2005 211 220
82. Ullmann AJ, Cornely OA, Burchardt A, et al. Safety and efficacy of posaconazole in a pharmacokinetic study in patients with febrile neutropenia or refractory invasive fungal infections. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; Sept 14-17, 2003.
83. SG Lim, AM Sawyerr, M Hudson, J Sercombe, RE Pounder Short report: the absorption of fluconazole and itraconazole under conditions of low intragastric acidity Aliment Pharmacol Ther 7 1993 317 321
84. P Krieter, B Flannery, T Musick, M Gohdes, M Martinho, R Courtney Disposition of posaconazole following single-dose oral administration in healthy subjects Antimicrob Agents Chemother 48 2004 3543 3551
85. AH Groll, JC Gea-Banacloche, A Glasmacher, G Just-Nuebling, G Maschmeyer, TJ Walsh Clinical pharmacology of antifungal compounds Infect Dis Clin North Am 17 2003 159 191
86. RD Courtney, M Laughlin, H Gontz Single-dose pharmacokinetics of posaconazole in subjects with various degrees of chronic liver disease AAPS PharmSci 2 2000 A1852
87. R Courtney, S Pai, M Laughlin, J Lim, V Batra Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults Antimicrob Agents Chemother 47 2003 2788 2795
88. Stevens DA. New azoles. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Canada; Sept 7-12, 2000.
89. Krishna G, Wexler D, Courtney R, et al. Posaconazole plasma concentrations in pediatric patients with invasive fungal infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Oct 30-Nov 2, 2004.
90. TE Zaoutis, DK Benjamin, WJ Steinbach Antifungal treatment in pediatric patients Drug Resist Updat 8 2005 235 245
91. C Antachopoulos, TJ Walsh New agents for invasive mycoses in children Curr Opin Pediatr 17 2005 78 87
92. R Courtney, A Sansone, W Smith Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease J Clin Pharmacol 45 2005 185 192
93. P Pitisuttithum, R Negroni, J Graybill Activity of posaconazole in the treatment of central nervous system fungal infections J Antimicrob Chemother 56 2005 745 755
94. HM Al-Abdely, AM Alkhunaizi, JA Al-Tawfiq, M Hassounah, MG Rinaldi, DA Sutton Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole Med Mycol 43 2005 91 95
95. Raad II, Boktour MR, Hanna HA, Kontoyiannis DP, Hachem RY. Posaconazole compared to amphotericin B lipid formulations alone or in combination with itraconazole as salvage therapy for invasive aspergillosis in patients with hematologic malignancy. 42nd Meeting of the Infectious Diseases Society of America; Boston, MA, USA; Sept 30-Oct 3, 2004.
96. Perfect JR, Graham DR, Corcoran G, Pedicone L, Raad II. Posaconazole safety and efficacy in elderly patients with invasive fungal infections. 42nd Meeting of the Infectious Diseases Society of America; Boston, MA, USA; Sept 30-Oct 3, 2004.
97. Nieto L, Northland R, Pittisuttithum P, et al. Posaconazole equivalent to fluconazole in the treatment of oropharyngeal candidiasis. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Canada; Sept 7-12, 2000.
98. Greenberg RN, Anstead G, Herbrecht R, et al. Posaconazole experience in the treatment of zygomycosis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; Sept 14-17, 2003.
99. Negroni R, Tobon A, Bustamante A, Yasuda MAS, Hare R, Patino H. Posaconazole treatment of mycetoma and chromoblastomycosis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; Sept 14-17, 2003.
100. Restrepo A, Clark B, Graham D, et al. Treatment of histoplasmosis with posaconazole. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; Sept 14-17, 2003.
101. Stevens DA, Rendon A, Gaona V, et al. Posaconazole therapy for chronic refractory coccidioidomycosis. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington DC, USA; Oct 30-Nov 2, 2004.
102. Raad I, Chapman S, Bradsher R, et al. Posaconazole salvage therapy for invasive fungal infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Oct 30-Nov 2, 2004.
103. Raad I, Hachem R, Herbrecht R, Hare RS, Corcoran G. Experience of posaconazole in patients with fusariosis. 13th International Symposium on Infections in the Immunocompromised Host; Granada, Spain; June 27-30, 2004.
104. T Walsh, T Patterson, A Langston Posaconazole for treatment of invasive aspergillosis in patients who are refractory to or intolerant of conventional therapy: an externally controlled blinded trial Blood 2003 195a 196a
105. Skiest DJ, Vazquez JA, Graybill JR, et al. Open-label trial of posaconazole (POS) for azole-refractory oropharyngeal and esophageal candidiasis in HIV/AIDS patients: final analysis. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Oct 30-Nov 2, 2004.
106. Hachem RY, Graybill JR, Negroni R, et al. Posaconazole as salvage therapy for Pseudallescheria infections: a case series. 14th European Congress of Clinical Microbiology and Infectious Diseases; Prague, Czech Republic; May 1-4, 2004.
107. Hachem R, Raad I, Afif C, et al. An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections refractory to or intolerant of standard therapy. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Canada; Sept 7-12, 2000.
108. Courtney RD, Statkevich P, Laughlin M, et al. Potential for a drug interaction between posaconazole and phenytoin. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; Dec 6-9, 2001.
109. Courtney RD, Statkevich P, Laughlin M, et al. Potential for a drug interaction between posaconazole and rifabutin. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, IL, USA; Dec 6-9, 2001.
110. Courtney R, Wexler D, Statkevich P, Lim J, Batra V, Laughlin M. Effect of cimetidine on the pharmacokinetics of posaconazole in healthy volunteers. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; San Diego, USA; Sept 27-30, 2002.
111. L Gerzenshtein, SM Patel, KK Scarsi, MJ Postelnick, JP Flaherty Breakthrough Candida infections in patients receiving voriconazole Ann Pharmacother 39 2005 1342 1345
112. R Herbrecht, Y Nivoix, C Fohrer, S Natarajan-Ame, V Letscher-Bru Management of systemic fungal infections: alternatives to itraconazole J Antimicrob Chemother 56 suppl 1 2005 i39 i48
113. ES Dodds Ashley, BD Alexander Posaconazole Drugs Today (Barc) 41 2005 393 400
114. AM Tobon, AL Correa, M Arango, C de Bedout, A Restrepo Posaconazole therapy for severe abdominal candidiasis: a case report Rev Iberoam Micol 21 2004 79 81
115. BA Lodge, ED Ashley, MP Steele, JR Perfect Aspergillus fumigatus empyema, arthritis, and calcaneal osteomyelitis in a lung transplant patient successfully treated with posaconazole J Clin Microbiol 42 1 2004 376 378
116. AM Tobon, M Arango, D Fernandez, A Restrepo Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy Clin Infect Dis 36 2003 1488 1491
117. BH Segal, LA Barnhart, VL Anderson, TJ Walsh, HL Malech, SM Holland Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection Clin Infect Dis 40 2005 1684 1688
118. Herbrecht R, Marr K, Catanzaro A, et al. Posaconazole (POS) as salvage therapy for invasive fungal infections unresponsive to voriconazole: a case series. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Oct 30 - Nov 2, 2004.
119. Vazquez JA, Northland R, Miller S, Dickinson G, Wright G. Posaconazole compared to fluconazole for oral candidiasis in HIV-positive patients. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Canada; Sept 7-12, 2000.
120. SM Wynne, KJ Kwon-Chung, YR Shea Invasive infection with Trichosporon inkin in 2 siblings with chronic granulomatous disease J Allergy Clin Immunol 114 2004 1418 1424
121. Raad II, Boktour MR, Hanna HA, Kontoyiannis DP, Hachem RY. Posaconazole compared to amphotericin B lipid formulations in combination with caspofungin as salvage therapy for invasive aspergillosis in patients with hematologic malignancy. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Oct 30-Nov 2, 2004.
122. R Herbrecht, R Kessler, C Kravanja, MH Meyer, J Waller, V Letscher-Bru Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient J Heart Lung Transplant 23 2004 1451 1454
123. WE Sponsel, JR Graybill, HL Nevarez, D Dang Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis Br J Ophthalmol 86 2002 829 830
124. CA Kauffman Zygomycosis: reemergence of an old pathogen Clin Infect Dis 39 2004 588 590
125. DP Kontoyiannis, MS Lionakis, RE Lewis Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases J Infect Dis 191 2005 1350 1359
126. DP Kontoyiannis, VC Wessel, GP Bodey, KV Rolston Zygomycosis in the 1990s in a tertiary-care cancer center Clin Infect Dis 30 2000 851 856
127. L Ide, I Buysschaert, H Demuynck Zygomycosis in neutropenic patients with past Aspergillus infection: a role for posaconazole? Clin Microbiol Infect 10 2004 862 863
128. Roden MM, Buchanan W, Knudsen T, et al. Epidemiology and outcome of zygomycosis: a review of 631 cases. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Oct 30 - Nov 2, 2004.
129. L Pagano, M Offidani, L Fianchi Mucormycosis in hematologic patients Haematologica 89 2004 207 214
130. JA Ribes, CL Vanover-Sams, DJ Baker Zygomycetes in human disease Clin Microbiol Rev 13 2000 236 301
131. MS Lionakis, DP Kontoyiannis Sinus zygomycosis in a patient receiving voriconazole prophylaxis Br J Haematol 129 2005 2
132. IK Mellinghoff, DJ Winston, G Mukwaya, GJ Schiller Treatment of Scedosporium apiospermum brain abscesses with posaconazole Clin Infect Dis 34 2002 1648 1650
133. R Herbrecht, V Letscher-Bru, C Fohrer Acremonium strictum pulmonary infection in a leukemic patient successfully treated with posaconazole after failure of amphotericin B Eur J Clin Microbiol Infect Dis 21 2002 814 817
134. HA Torres, GA Rivero, DP Kontoyiannis Endemic mycoses in a cancer hospital Medicine (Baltimore) 81 2002 201 212
135. J Wheat Endemic mycoses in AIDS: a clinical review Clin Microbiol Rev 8 1995 146 159
136. GM Anstead, G Corcoran, J Lewis, D Berg, JR Graybill Refractory coccidioidomycosis treated with posaconazole Clin Infect Dis 40 2005 1770 1776
137. Graybill JR, Raad I, Negroni R, Corcoran G, Pedicone L. Posaconazole long-term safety in patients with invasive fungal infections. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Oct 30-Nov 2, 2004.
138. Sansone A, Courtney R, Brundage T, Laughlin M. Safety and tolerability of posaconazole: Evaluation of 18 controlled healthy volunteer studies. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Oct 30-Nov 2, 2004.
139. Sansone A, Courtney R, Mellars L, et al. Posaconazole has no clinically significant effect on the QTc interval in healthy volunteers. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC, USA; Oct 30-Nov 2, 2004.